News

Chembio Develops Rapid COVID-19 Test

Chembio Diagnostics, a Long Island based leading point-of-care diagnostic company, which focuses on
developing tests for infectious diseases, on March 20 said it obtained the order from
Bio-Manguinhos for its DPP COVID-19 IgM/IgG System. Chembio’s product is a single-use,
rapid point-of-care test that detects certain antibodies to COVID-19 in blood via
fingerstick, using a handheld analyzer. The company uses a patented technology requiring
a small drop of blood from the fingertip and a disposable test to provide results
in approximately 15 minutes.
(Read more)

Chembio and LumiraDx Announce COVID-19 Strategic Partnership

Chembio Diagnostics announced that it has entered into a worldwide strategic partnership with LumiraDx
Limited to develop point-of-care (POC) diagnostic tests for the detection of the COVID-19
virus and IgM and IgG antibodies on both the LumiraDx and Chembio DPP platforms.
(Read more)

Congratulations to Dr. Iwao Ojima and his team, Dr. Martin Kaczocha, Dr. Robert Rizzo
(ICB&DD) and Dr. Lloyd Trotman (Cold Spring Harbor), who received a $4.2 million five-
year grant from the National Cancer Institute.

Their project entitled “Development of the Next Generation of FABP5 Inhibitors to
Treat Prostate Cancer” will investigate a specific fatty acid binding protein (FABP)
inhibitors for the treatment of drug- resistant and metastatic prostate cancer, either
by themselves or in combination with other therapeutics.
Read more and
SOM News

Message from the Director

Dr. Iwao Ojima, Distinguished Professor and Director, ICB&DD

Welcome to the Institute of Chemical Biology & Drug Discovery

The primary objective of ICB&DD is to establish a world-class “
Center of Excellence” in chemical biology and drug discovery at Stony Brook. The rapid and impressive
advancement of chemical biology in the last decades clearly demonstrated that solutions
for vast majority of medical problems rely on the understanding of the molecular basis
of diseases, therapeutic targets, drug actions, and drug resistance. ICB&DD promotes
highly productive interdisciplinary and multidisciplinary research bridging the West,
East and South campuses as well as Brookhaven National Laboratory to attack major
and significant biomedical problems to find solutions including the discovery of novel
therapeutic drugs. ICB&DD significantly contributes to the advancement of a truly
comprehensive biomedical research enterprise from molecular science to clinic at Stony
Brook.